Drugs that contain Angiotensin Ii Acetate
1. List of Giapreza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9867863 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US10335451 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US10548943 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US10500247 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US9572856 | LA JOLLA PHARMA | Method of treating low blood pressure |
Jul, 2031
(8 years from now) | |
| US11096983 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US10493124 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US9220745 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US10028995 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US11559559 | LA JOLLA PHARMA | NA |
Dec, 2034
(11 years from now) | |
| US11219662 | LA JOLLA PHARMA | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
Jan, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 21, 2022 |
NCE-1 date: 2021-12-21
Market Authorisation Date: 21 December, 2017
Treatment: Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angio...
Dosage: SOLUTION;INTRAVENOUS
How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic